Century Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Century Therapeutics, Inc. (NASDAQ: IPSC) is a clinical-stage biotechnology company pioneering the development of allogeneic, induced pluripotent stem cell (iPSC)-derived cell therapies. The company leverages its proprietary Allo-Evasion™ immune-evasion engineering technology to design off-the-shelf therapies that can bypass host immune rejection without requiring chronic immunosuppression. Century's pipeline targets high-impact therapeutic areas, specifically focusing on autoimmune diseases, such as Type 1 Diabetes (T1D), and various cancers. Its lead product candidates include CNTY-813, a potentially curative stem cell-derived islet replacement therapy for T1D, and CNTY-308, a CD19-targeted CAR-iT cell therapy. By utilizing a clonal master iPSC line foundry, Century aims to overcome the scalability, consistency, and high manufacturing cost limitations associated with first-generation autologous cell therapies.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Century Therapeutics restructured its pipeline to focus heavily on high-impact autoimmune disease programs, specifically prioritizing CNTY-813 (Type 1 diabetes) and CNTY-308 (B-cell mediated autoimmune diseases), while discontinuing or de-prioritizing certain oncology programs.
Expected impact: Aims to deliver differentiated, patient-centric, potentially curative cell therapies for autoimmune diseases and Type 1 diabetes.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of Clade Therapeutics to integrate its engineerable, off-the-shelf, and scalable stem cell-based medicines, focusing on iPSC-derived ̱̲ CD4+ and CD8+ T cells, and adding preclinical candidates CLDE-308 and CLDE-361 to Century's pipeline.
Financial impact: Acquired for approximately $35 million in upfront cash and stock, with an additional $10 million eligible for a clinical milestone payment.
Strategic Partnerships
The collaboration focused on developing stem cell-derived, engineered natural killer cell and gamma delta T cell candidates for blood cancers. BMS terminated the agreement without cause effective March 12, 2025, as part of its internal portfolio prioritization and cost-saving efforts.
Terms: Originally established in January 2022 with a $150 million upfront payment and equity investment. Century recognized $109.2 million of collaboration revenue in Q1 2025 upon termination, with no future collaboration revenues expected under this agreement.